Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors

2003 ◽  
Author(s):  
R. Kaufmann ◽  
U. Junker ◽  
M. Schilli-Westermann ◽  
C. Klötzer ◽  
J. Scheele ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Carcinoma Cells ◽  
Thrombin Receptors ◽  
Renal Carcinoma Cells

scholarly journals PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration

2006 ◽  
Author(s):  
Sebastian Bergmann ◽  
Kerstin Junker ◽  
Peter Henklein ◽  
Morley Hollenberg ◽  
Utz Settmacher ◽  
...  
Keyword(s):  
Cell Migration ◽  
Renal Carcinoma ◽  
Carcinoma Cells ◽  
Thrombin Receptors ◽  
Egfr Activation ◽  
Renal Carcinoma Cells

The Indolylcoumarin COUFIN Exhibits Potent Activity Against Renal Carcinoma Cells without Affecting Hematopoietic System

2014 ◽  
Vol 14 (6) ◽  
pp. 862-871 ◽  
Author(s):  
Pierre Champelovier ◽  
Pascale Barbier ◽  
Etienne Daras ◽  
Soazig Douillard ◽  
Bertrand Toussaint ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Carcinoma Cells ◽  
Hematopoietic System ◽  
Renal Carcinoma Cells

scholarly journals Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 576
Author(s):  
Sofia Giacosa ◽  
Catherine Pillet ◽  
Irinka Séraudie ◽  
Laurent Guyon ◽  
Yann Wallez ◽  
...  
Keyword(s):  
High Throughput Screening ◽  
Renal Carcinoma ◽  
Kinase Inhibitors ◽  
Ex Vivo ◽  
Cancer Therapeutics ◽  
Carcinoma Cells ◽  
Wild Type ◽  
Cell Renal Cell Carcinoma ◽  
Von Hippel Lindau ◽  
Renal Carcinoma Cells

Kinase-targeted agents demonstrate antitumor activity in advanced metastatic clear cell renal cell carcinoma (ccRCC), which remains largely incurable. Integration of genomic approaches through small-molecules and genetically based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. The 786-O cell line represents a model for most ccRCC that have a loss of functional pVHL (von Hippel-Lindau). A multiplexed assay was used to study the cellular fitness of a panel of engineered ccRCC isogenic 786-O VHL− cell lines in response to a collection of targeted cancer therapeutics including kinase inhibitors, allowing the interrogation of over 2880 drug–gene pairs. Among diverse patterns of drug sensitivities, investigation of the mechanistic effect of one selected drug combination on tumor spheroids and ex vivo renal tumor slice cultures showed that VHL-defective ccRCC cells were more vulnerable to the combined inhibition of the CK2 and ATM kinases than wild-type VHL cells. Importantly, we found that HIF-2α acts as a key mediator that potentiates the response to combined CK2/ATM inhibition by triggering ROS-dependent apoptosis. Importantly, our findings reveal a selective killing of VHL-deficient renal carcinoma cells and provide a rationale for a mechanism-based use of combined CK2/ATM inhibitors for improved patient care in metastatic VHL-ccRCC.

The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing

Autophagy ◽  
2015 ◽  
pp. 00-00 ◽  
Author(s):  
Yosra Messai ◽  
Muhammad Zaeem Noman ◽  
Bassam Janji ◽  
Meriem Hasmim ◽  
Bernard Escudier ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Carcinoma Cells ◽  
Renal Carcinoma Cells

scholarly journals Suppression of Hypoxia-Inducible Factor 2α Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells

2009 ◽  
Vol 69 (23) ◽  
pp. 9056-9064 ◽  
Author(s):  
Andrew M. Roberts ◽  
Ian R. Watson ◽  
Andrew J. Evans ◽  
David A. Foster ◽  
Meredith S. Irwin ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Hypoxia Inducible Factor ◽  
Carcinoma Cells ◽  
Renal Carcinoma Cells
Sign in / Sign up

Export Citation Format

Share Document